- Company
- Losartan products are about to be withdrawn from the market
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- With the recovery of Losartan with excessively detected impurities, pharmaceutical companies are considering strategies after recovery measures are completed. Many pharmaceutical companies that did not have a very high market share in the Losartan market are reportedly considering gradually withdrawing from the market after the recovery is co
- Company
- EMA designated Hanmi's HM15211 as ODD
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- Hanmi Pharmaceutical's LAPSTriple Agonist, HM15211 announced on the 17th that it has been designated as ODD by the European Medicines Agency (EMA). According to Hanmi Pharmaceutical, EMA recently designated it as ODD for the treatment of primary sclerosing cholangitis, PSC. The LAPSTriple Agonist has previously been designated as ODD by th
- Company
- Myung In’s Parkinson’s Tx demonstrates efficacy
- by Dec 20, 2021 06:12am
- A Parkinson’s disease treatment that Myung In Pharm has acquired an exclusive licensing agreement from an Israeli pharmaceutical company - 'P2B001 (Fixed-dose combination of pramipexole+rasagiline)’ &8211; has demonstrated its safety and efficacy at a global Phase III clinical trial. According to the topline results announced by the Is
- Company
- Expectations rise for Lilly’s Alzheimer drug
- by Eo, Yun-Ho Dec 20, 2021 06:11am
- Expectations have been rising for the commercialization of Lilly’s new drug candidate for Alzheimer’s. On the 15th (local time), Eli Lilly announced that it will complete filing for approval of its new Alzheimer’s candidate ‘donanemab’ within the first quarter of 2022. The news was announced at an investor meeting while introducin
- Company
- Ildong signed for Nexium worth ₩50 billion
- by Dec 20, 2021 06:11am
- AstraZeneca Korea announced on the 14th that it has signed a partnership contract with Ildong for gastroesophageal reflux disease treatment "Nexium (Esomeprazole)" and type 2 diabetes treatment "Qtern (Dapagliflozin/Saxagliptin Monohydrate)." Through this, Ildong Pharmaceutical will jointly sell Nexium and Qtern with AstraZeneca Korea from
- Company
- New depression drug Spravato lands in the 'Big 5' Hospitals
- by Eo, Yun-Ho Dec 16, 2021 05:52am
- Janssen’s new drug for depression, ‘Spravato,’ can now be prescribed at general hospitals in Korea. According to industry sources, Spravato (esketamine) that is used in combination with an oral antidepressant, has passed the review of drug committees (DC) of 80 medical institutions in the nation including the 'Big-5' general hospitals
- Company
- Dupixent can be used by all age groups
- by Dec 16, 2021 05:51am
- Dupixent, atopic dermatitis (Eczema) treatment that marks its third anniversary, is becoming the only biological agent available for all ages. Doctors agreed, "It is time to show flexibility in applying Dupixent benefits that have secured long-term effectiveness and safety." At an online seminar held by Sanofi to mark the 3rd anniversary
- Company
- Pfizer’s NSCLC drug Vizimpro to be prescribed at GHs
- by Eo, Yun-Ho Dec 14, 2021 05:57am
- Pfizer’s EGFR TKI Vizimpro may now be prescribed at general hospitals. According to industry sources, Pfizer Korea’s Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib) passed the Drug Committees (DCs) of four of the Big-5s - Samsung Medical Center (SMC), Seoul National University Hospital (SNU
- Company
- Sang Wook Kang, CEO of GSK consumer healthcare, resigned
- by Eo, Yun-Ho Dec 14, 2021 05:57am
- The CEO of GSK and Novartis' OTC joint venture "GSK Consumer Healthcare" is expected to be replaced. According to related industries, Kang Sang-wook (45) CEO of GSK Consumer Healthcare Korea recently resigned. As a result, CEO Kang will leave the company about three years after taking office in January 2019. He entered the pharmaceutical i
- Company
- Boehringer loses another ‘Trajenta’ trademark dispute
- by Kim, Jin-Gu Dec 13, 2021 05:57am
- Boehringer Ingelheim once again tasted defeat in a trademark dispute over its DPP-4 inhibitor antidiabetic ‘Trajenta (linagliptin).' In addition to the trademark dispute against Kwangdong Pharmaceutical in 2019, the company recently lost once more in a suit against Daewoong Pharmaceutical. According to the industry on the 13th, the In
